tremelimumab + leuprolide acetate + bicalutamide

This is a **combination drug regimen** comprised of three agents: - **Tremelimumab**: a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), activating T cells and promoting antitumor immune responses. - **Leuprolide acetate**: a synthetic gonadotropin-releasing hormone (GnRH) agonist that suppresses testosterone production by downregulating the pituitary-gonadal axis, primarily used in androgen deprivation therapy. - **Bicalutamide**: a nonsteroidal antiandrogen that competitively inhibits androgen receptors, preventing the effects of testosterone and dihydrotestosterone. This triple regimen may be investigated for advanced cancers, particularly those responsive to androgen deprivation and immunotherapy mechanisms, such as prostate cancer and potentially androgen receptor–positive salivary gland cancers[1][2][3]. No unique brand for the combined use is established; it is a regimen sometimes considered in clinical or investigational contexts.

Brand names

CasodexEligard

Other names

bicalutamideleuprolide acetateleuprorelin acetate